2016
DOI: 10.1136/gutjnl-2016-311609
|View full text |Cite
|
Sign up to set email alerts
|

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study

Abstract: ObjectiveDue to a high efficacy in clinical trials, sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and effectiveness of these regimens for GT2 in HCV-TARGET participants.DesignHCV-TARGET, an international, prospective observational study evaluates clinical practice data on novel antiviral therapies at 44 academic and 17 community medical centres in North America and Europe. Clinical data were centrally … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

13
92
2

Year Published

2016
2016
2021
2021

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 76 publications
(107 citation statements)
references
References 29 publications
(30 reference statements)
13
92
2
Order By: Relevance
“…High rates of SVR with the combination SOF + RBV were more similar to those described in Asian CTs[23] than the SVR of 79.0% or 86.2% achieved in clinical practice in the two VA studies[14,18] or the SVR of 88.2% from the recent analysis of 321 genotype 2 HCV infected HCV-TARGET participants[24]. However, the low number of genotype 2 patients in our study indicate that several of the currently recommended combinations in clinical guidelines, such as SOF and DCV[25] should be favored because they presented 100% SVR rates in all patients.…”
Section: Discussionsupporting
confidence: 54%
“…High rates of SVR with the combination SOF + RBV were more similar to those described in Asian CTs[23] than the SVR of 79.0% or 86.2% achieved in clinical practice in the two VA studies[14,18] or the SVR of 88.2% from the recent analysis of 321 genotype 2 HCV infected HCV-TARGET participants[24]. However, the low number of genotype 2 patients in our study indicate that several of the currently recommended combinations in clinical guidelines, such as SOF and DCV[25] should be favored because they presented 100% SVR rates in all patients.…”
Section: Discussionsupporting
confidence: 54%
“…However, drug discontinuation occurred in 2.5 % (G2) and 3.2 % (G3) of patients. Death occurred in 5 patients (1 %) unrelated to the study drugs [98]. However, a recent analysis is a cause for concern with 13 of 42 patients with post transplant rHCV infection developing serious adverse event or hepatic decompensation following regimens containing sofosbuvir and ribavirin.…”
Section: Adverse Events Of Daasmentioning
confidence: 90%
“…All patients with HCV RNA <45 IU/ml according to CAP/CTM or <60 IU/ml according to the ART assay achieved SVR, while patients with a week 2 HCV RNA above the respective cut-offs achieved SVR in 33% and 29% only [40] (Table 3). SOF/RBV is widely considered as standard of care in genotype 2 patients and high SVR rates exceeding 88% have been reported [35,95]. As a result, on-treatment HCV RNA was not predictive of SVR in genotype 2 patients treated with SOF/ RBV for 12 weeks in the VALENCE study [94].…”
Section: Key Pointmentioning
confidence: 90%